2,400
Participants
Start Date
February 29, 2016
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2026
RAS-antagonist and beta-blocker up-to maximal dosages
All patients have to be stable on their glucose lowering, lipid lowering and blood pressure lowering therapy at least for 3 months. RAS-antagonist and beta-blocker therapy at entrance is allowed. Patients receive a prescription and/or up-titration to maximum recommended or tolerated dose of RAS-antagonist and beta-blockers within three months of study entry. The Number of titration visits is up to the treating physician, but one visit should be performed at least at the end of titration.
RAS-antagonist and beta-blocker none or at stable dose
All patients have to be stable on their glucose lowering, lipid lowering and blood pressure lowering therapy at least for 3 months. RAS-antagonist and beta-blocker therapy at entrance is allowed. Changes in RAS-antagonist or beta-blocker therapy are not allowed in the control group during the study phase. If there is a vital indication for changes, this has to be argued and documented.
COMPLETED
Krankenanstalt Rudolfstiftung, 1. Medizinische Abteilung, Vienna
TERMINATED
Zentrum für Klinische Studien, Vienna
RECRUITING
Medical University of Vienna Univ.Clinic for Internal Medicine II Department of Cardiology, Vienna
RECRUITING
Univ. Klinik für Innere Medizin III Med. Uni Wien, Vienna
RECRUITING
Universitätsklinik für Augenheilkunde und Optometrie Medizinische Universität Wien, Vienna
RECRUITING
Diabetes & Stoffwechselambulanz Gesundheitszentrum Wien Süd, Vienna
TERMINATED
3. Med. Abtlg., KH Hietzing mit Neurologischem Zentrum Rosenhügel, Vienna
RECRUITING
iMED19, Vienna
ACTIVE_NOT_RECRUITING
Internistische Ordination, Mödling
RECRUITING
Konventhospital der Barmherzigen Brüder Abteilung für Innere Medizin, Linz
ACTIVE_NOT_RECRUITING
Maastricht University Medical Center; Dep. Cardiology, Maastricht
RECRUITING
Hospital de la Santa Creu i Sant Pau, Unitat de Diabetis, Servei d'Endocrinologia i Nutrició, Universitat Autònoma de Barcelona, Barcelona
RECRUITING
Klinischen Abteilung für Endokrinologie und Diabetologie MU Graz, Graz
RECRUITING
Christchurch Heart Institute, Christchurch
RECRUITING
Hospital Universitari Germans Trias i Pujol, l'Institut del Cor, Barcelona
RECRUITING
Ninewells Hospital, Diabetes Support Unit, Dundee
RECRUITING
Queen Elisabeth University Hospital, Glasgow Clinical Research Facility, Glasgow
RECRUITING
North Manchester General Hospital, Diabetes centre, Manchester
ACTIVE_NOT_RECRUITING
Nethergreen Surgery, Sheffield
ACTIVE_NOT_RECRUITING
Ecclesfield Group Practice, Sheffield
ACTIVE_NOT_RECRUITING
Woodseats Medical Centre, Sheffield
Martin Huelsmann
OTHER